Table 1.
Characteristic | Cohort | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
ADCa | University of Toronto/ GSKb |
Miamic | NIMHb | NIA-LOADb | NCRADb | MIRAGEb | Genetic Differencesb |
ACTb | WHICAPb | Washington Universityd |
Total | |
Samples, No. (A673T heterozygotes, No.) | ||||||||||||
Cases | 3930 (0) | 152 (0) | 936 (0) | 354 (0) | 749 (0) | 395 (0) | 576 (0) | 239 (0) | 282 (1) | 54 (0) | 554 (0) | 8221 (1) |
Controls | 2326 (0) | 0 | 995 (0) | 0 | 458 (0) | 0 | 12 (0) | 216 (0) | 1445 (1) | 322 (0) | 360 (0) | 6134 (1) |
Total | 6256 (0) | 152 (0) | 1931 (0) | 354 (0) | 1207 (0) | 395 (0) | 588 (0) | 455 (0) | 1727 (2) | 376 (0) | 914 (0) | 14 355 (2) |
Male, % | 43.6 | 46.1 | 38.5 | 28.0 | 39.4 | 31.9 | 38.4 | 35.8 | 43.4 | 39.9 | 40.4 | 41.1 |
Case age at onset | ||||||||||||
Mean (SD), y | 72.4 (9.3) | 77.8 (6.8) | 72.6 (7.1) | 71.6 (8.1) | 73.8 (7.2) | 71.0 (8.5) | 68.6 (8.7) | 76.4 (6.2) | 83.7 (4.7) | 84.5 (7.2) | 79.8 (9.7) | 73.4 (9.1) |
No. | 3930 | 152 | 885 | 354 | 749 | 393 | 572 | 239 | 282 | 54 | 554 | 6130 |
Control age at last examination | ||||||||||||
Mean (SD), y | 77.2 (9.3) | NA | 73.5 (7.9) | NA | 79.6 (8.7) | NA | 76.1 (7.8) | 80.8 (6.6) | 81.6 (6.1) | 81.0 (6.1) | 74.6 (8.7) | 78.0 (8.6) |
No. | 2326 | NA | 991 | NA | 458 | NA | 12 | 216 | 1445 | 322 | 360 | 8164 |
Cohort type | Case-control | Case-control | Case-control | Multiplex families | Multiplex families | Multiplex families | Multiplex families | Population-based incident cases with matched controls | Prospective cohort | Prospective cohort | Case-control |
Abbreviations: ACT, Adult Changes in Thought; ADC, Alzheimer’s Disease Centers; GSK, GlaxoSmithKline; MIRAGE, Multi-institutional Research in Alzheimer’s Genetic Epidemiology; NA, not applicable; NCRAD, National Cell Repository for Alzheimer’s Disease; NIA-LOAD, National Institute on Aging–Late-Onset Alzheimer’s Disease; NIMH, National Institute of Mental Health; WHICAP, Washington Heights–Inwood Columbia Aging Project.
In this cohort, 3640 cases and 2223 controls were genotyped at the Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research, Manhasset, New York (as 2 batches) and 282 cases and 103 controls were genotyped at the Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania.
Genotyped at the Center for Applied Genomics, The Children’s Hospital of Philadelphia, Philadelphia, Pennsylvania.
Genotyped at the John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida.
Genotyped at the Robert S. Boas Center for Genomics and Human Genetics, Feinstein Institute for Medical Research.